Cryo-Cell International (CCEL) AI Stock Analysis

• Market Cap: $36.60M
• Dividend Yield: 9.07%
• Average Volume (3M): 24.49K
• Price to Earnings (P/E): 380.0
• Beta (1Y): 0.02
• Revenue Growth: 1.10%
• EPS Growth: 98.13%
• Country: US
• Employees: 82
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.04
• Shares Outstanding: 8,062,159
• 10 Day Avg. Volume: 10,287
• 30 Day Avg. Volume: 24,489
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.45
• Enterprise Value/Revenue: 1.65
• Enterprise Value/Gross Profit: 2.17
• Enterprise Value/Ebitda: 14.62
• 1Y Price Target: $6.50
• Price Target Upside: 47.39% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 54 Neutral
• Price Target: $4.50 ▲(2.04% Upside)

Cryo-Cell International's overall stock score is primarily impacted by its financial performance and valuation. The company's strong cash flow generation provides some financial flexibility, but significant balance sheet concerns and low profitability margins weigh heavily. Technical analysis offers mixed signals, while the high dividend yield is a positive aspect in an otherwise challenging valuation scenario.

Positive Factors

Cash Generation Ability

Strong cash generation provides financial flexibility, allowing the company to invest in growth opportunities and manage debt, even with low net income.

Revenue Growth Trends

Stable revenue growth indicates a consistent demand for services, supporting long-term business sustainability and potential for market expansion.

Gross Profit Margin

A strong gross profit margin suggests effective cost management and pricing power, which can support profitability improvements over time.

Negative Factors

Negative Equity

Negative equity highlights financial instability and potential insolvency risks, necessitating urgent capital restructuring to ensure long-term viability.

Low Profitability Margins

Low profitability margins reflect operational inefficiencies, limiting the company's ability to reinvest in growth and affecting long-term financial health.

High Operational Costs

High operational costs reduce profitability, hindering the company's capacity to improve margins and invest in strategic initiatives for growth.

Cryo-Cell International Business Overview & Revenue Model

Company Description

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

How the Company Makes Money

Cryo-Cell International generates revenue primarily through its cord blood and tissue banking services. The company charges families an initial fee for the collection and processing of stem cells, followed by annual storage fees for maintaining the samples in their facilities. Additional revenue streams include partnerships with healthcare providers, research institutions, and participation in clinical trials, which may involve collaboration in the development of new treatments leveraging stem cells. Furthermore, Cryo-Cell's public cord blood bank contributes to its reputation and outreach, potentially attracting more private clients. The company's growth and earnings are also bolstered by strategic partnerships and advancements in regenerative medicine, which enhance the perceived value of stem cell storage among consumers.

Cryo-Cell International Financial Statement Overview

Summary

Cryo-Cell International's financial performance shows a stable revenue base but significant profitability and balance sheet challenges. The income statement indicates high operational costs impacting net profit. The balance sheet is under pressure with negative equity, highlighting financial instability. However, the cash flow statement provides a silver lining with strong cash generation capabilities, suggesting potential for operational turnaround with improved cost management and strategic financial restructuring.

Income Statement

The income statement shows stable revenue with slight growth over the years, but profitability margins are concerning. The TTM gross profit margin is robust at 76.2%, yet the net profit margin is very low at 0.8%, indicating high operational costs. EBIT and EBITDA margins are 11.9% and 6.9% respectively, which show operational challenges. Revenue growth is modest, but profitability issues suggest room for efficiency improvements.

Balance Sheet

The balance sheet reveals significant financial risks with negative stockholders' equity of -$15.56 million, highlighting insolvency concerns. The debt-to-equity ratio cannot be calculated due to negative equity, indicating a leveraged position. Total assets are declining, and the equity ratio is negative, emphasizing financial instability. Overall, the balance sheet suggests urgent need for capital restructuring.

Cash Flow

Cash flow analysis shows strong operating cash flow relative to net income, with a TTM operating cash flow of $6.26 million and a free cash flow of $5.67 million. The free cash flow growth is positive, reflecting effective cash management despite low net income. The company has managed to maintain positive free cash flow, providing some financial flexibility amidst profitability challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	31.99M	31.34M	30.34M	28.88M	31.15M
Gross Profit	24.04M	22.90M	21.54M	19.90M	21.49M
EBITDA	1.42M	-10.42M	6.65M	5.32M	7.22M
Net Income	402.10K	-9.52M	2.77M	2.08M	3.62M
Balance Sheet
Total Assets	64.68M	61.22M	64.89M	60.66M	46.20M
Cash, Cash Equivalents and Short-Term Investments	3.50M	980.25K	1.72M	8.34M	10.45M
Total Debt	12.93M	10.90M	11.61M	2.82M	6.24M
Total Liabilities	77.89M	72.25M	66.41M	56.48M	48.87M
Stockholders Equity	-13.22M	-11.03M	-1.52M	4.18M	-2.67M
Cash Flow
Free Cash Flow	3.61M	1.28M	-8.60M	974.92K	8.02M
Operating Cash Flow	6.01M	8.92M	8.57M	7.93M	8.47M
Investing Cash Flow	-4.88M	-8.14M	-15.28M	-6.95M	357.49K
Financing Cash Flow	-979.12K	-2.07M	147.86K	-3.07M	-5.00M

Cryo-Cell International Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCEL, the sentiment is Negative. The current price of 4.41 is below the 20-day moving average (MA) of 4.63, below the 50-day MA of 4.65, and below the 200-day MA of 5.64, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 40.86 is Neutral, neither overbought nor oversold. The STOCH value of 5.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCEL.

Cryo-Cell International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CCEL	54 Neutral	$36.60M	380.00	93.38%	9.07%	1.10%	98.13%
DCGO	54 Neutral	$121.28M	12.68	-5.98%	―	-41.31%	-163.08%
AMS	53 Neutral	$16.73M	11.72	-9.49%	―	26.61%	-156.30%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PIII	48 Neutral	$64.04M	―	-138.17%	―	4.20%	-54.16%
CCM	44 Neutral	$24.75M	―	14.03%	―	-22.38%	56.66%
MODVQ	40 Underperform	$2.86M	―	-951.52%	―	-0.70%	-2.38%

Cryo-Cell International Corporate Events

Cryo-Cell Schedules 2025 Annual Stockholders Meeting

Cryo-Cell International has scheduled its 2025 Annual Meeting of Stockholders for October 21, 2025, with a record date of September 15, 2025, for determining eligible stockholders. Stockholders must submit notices for business or director nominations within ten days of the public disclosure date, September 10, 2025, as per the company’s bylaws.

The most recent analyst rating on (CCEL) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Cryo-Cell International stock, see the CCEL Stock Forecast page.